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ABSTRACT
Asia is almost certainly a part of the world in which extended-spectrum b-lactamases (ESBLs) have
emerged de novo, with some early antimicrobial resistance studies showing high levels of the ESBL
phenotype, particularly among Klebsiella, and most notably in China, Korea, Japan and India. There is a
lack of genotyping studies but work from the late 1990s suggests that SHV-5 and SHV-12 were most
common then, with only very rare reports of TEM-related ESBL genes. As in other parts of the world,
quite marked differences have since been seen in the pattern of ESBL genes, particularly in relation to
the CTX-M family. The early emergence of TOHO CTX-M-2 in Japan contrasted with CTX-M-3 and -14
in China and many other parts of the Far East, suggesting the separate transfer of genes from the
genome of Kluyvera spp. to mobile genetic elements in human-associated Enterobacteriaceae. ESBL
production rates are now very high compared with Europe. In most countries, there are mixtures of
CTX-M types, with VEB appearing signiﬁcantly in Vietnam and Thailand, and ESBL isolates from India
being completely dominated by the presence of blaCTX-M-15 alone, with no other CTX-M types reported.
With the total population of India and China being c. 2.4 billion and with faecal carriage rates of,
probably, c. 10%, these countries represent major reservoirs of blaCTX-M genes. Increasing international
travel and trade will lead to the movement of many of these ESBL genes. The high prevalence of ESBL
genes in Asia means that the empirical treatment of serious infections with b-lactam antibiotics, except
carbapenems, is seriously compromised.
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Asia probably has a long history of the occurrence
of extended-spectrum b-lactamase (ESBL)-pro-
ducing bacteria. Excepting a few centres, interest
in ESBLs in the region is a comparatively recent
phenomenon and, as in other regions of the
world, coverage has not been comprehensive,
particularly in relation to genotypes. It is well-
recognised that there can be marked variation in
the incidence and or genotype of ESBLs in
hospitals close to one another, and certainly
among countries [1].
There were no comprehensive reports on the
incidence of ESBLs from countries in the region in
the 1980s and early 1990s. There were, however, a
number of sporadic reports of ESBLs, notably of
the SHV-2 type, from China in 1988 [2], and the
Toho-1 ESBL produced by Escherichia coli from
Japan in 1993 [3]. The recognition of the impor-
tance of ESBLs as a major mechanism of b-lactam
resistance throughout the region came with pre-
sentation of data from the 1998–1999 SENTRY
antimicrobial surveillance programme [4]. The
incidence of ESBL production (no genotyping was
undertaken) among E. coli isolates in the four
Chinese sites varied from 13% to 35%. Rates
‡20% for the ESBL phenotype in Klebsiella pneu-
moniae in all participating mainland Chinese
centres (one reaching 60%), in one each of three
Japanese and Taiwanese centres, and in the single
Singapore centre and Philippines centre, were
conﬁrmed. Such high rates had previously been
reported only from South America; in a follow-up
study (1998–2002), lower rates were found in
K. pneumoniae isolates from Australia and Japan
(£10%), but that in China was 30% [5]. The other
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area of Asia with high reported rates of ESBL
production is the Indian subcontinent. One study
reported a 68% prevalence of ESBL phenotypes
among E. coli and K. pneumoniae isolates, one of
the highest rates reported for any country world-
wide [6]. A number of other studies have reported
high rates in India [7], with a similar situation
existing in Pakistan [8].
Although SHV-type ESBLs apparently domi-
nated most studies in Asia, where genotyping
was ﬁrst undertaken in the 1990s [9], the data are
sparse because so few isolates from that era were
examined. It is certainly true that SHV-5 and -12
enzymes were reported in early studies from
Japan and Korea and remain quite common in
more recent studies [10–12]. But as in Europe, it is
the emerging dominance of CTX-M b-lactamases
that has changed the nature and signiﬁcance of
ESBL production in Enterobacteriaceae. It seems
likely that, particularly in China and India, where
high rates of ESBL production were reported in
the 1990s, CTX-M enzyme production had ex-
panded from the very early 1990s or late 1980s.
Interesting regional and national variations
apparently exist in blaCTX-M genotypes, although
a number of studies only report ‘group’ genotyp-
ing. In China, and a number of other Asian
countries, the dominant types are CTX-M-14 and
CTX-M-3, but Japan had a different proﬁle, with
CTX-M-2 being a common type. [13]. These
epidemiological aspects are considered below.
CHINA
Although one of the early reports of SHV-2
enzymes was from China [2], there were very
few further reports of ESBL genotypes until the
ﬁrst description of CTX-M-13 and CTX-M-14 (one
of the most numerous genotypes in Asia) from
isolates of four different species collected from
Guangzhou in 1997–1998. In total, 12 ⁄ 15 isolates
with ESBLs from this study carried blaCTX-M
genes, CTX-M-14 being the most common, fol-
lowed by CTX-M-9, ﬁrst identiﬁed in 2000 from
Spain [14]. In that study too, SHV-12 was reported
for the ﬁrst time in China, while a subsequent
large-scale study of isolates from six provinces,
collected between 1998 and 2002, reported SHV-
12 as the most common SHV type (ten isolates),
with much smaller numbers of SHV-5, -2 and -9
[15]. Nevertheless, the 17 isolates from that study
with blaSHV were dwarfed by the 288 isolates of
E. coli and 142 isolates of K. pneumoniae that
produced CTX-M b-lactamases. In both species,
CTX-M-14 (271 isolates) dominated, closely fol-
lowed by CTX-M-3 (70 isolates), a common
ﬁnding in other Chinese centres, as reviewed by
Munday et al. [13]. Yu et al. [15] reported some
rarer genotypes of blaCTX-M, namely CTX-M-13,
-22, -27 and -28, mainly as single isolates; the third
most common genotype was CTX-M-24 (35 iso-
lates), which is closely related to CTX-M-14.
High rates of ESBL production (with no geno-
typing) have been reported from various hospital
centres in China. Rarer types of ESBL have not
been reported, except for the ﬁrst description of
VEB-3 b-lactamase in 12 ⁄ 27 isolates of Enterobacter
cloacae from Shanghai (nine isolates also carried a
blaCTX-M-3-like gene); otherwise, VEB ESBLs are
most common in Vietnam and Thailand [16].
ESBLs were reported very early from Hong Kong,
with rates of 1.6% in E. coli and 2.6% in K. pneu-
moniae in 1990 [17]. Subsequently, rates rose
rapidly in mainland China, whereas they have
remained lower in Hong Kong, at 11% in E. coli
and 13% in K. pneumoniae in 1999 [18].
TAIWAN
The occurrence of ESBLs in Taiwan has been well-
documented and is reviewed in a recent publica-
tion [19]. Relatively high incidence ﬁgures (for
that time) for ESBL phenotypes were reported for
three centres in northern Taiwan, contributing to
the 1998–2002 SENTRY programme, with overall
rates of ESBL production of 13.5% in K. pneumo-
niae and 5.6% in E. coli [5]. The increase over time
in ESBL-producing K. pneumoniae isolates is illus-
trated in a single centre in northern Taiwan,
where they increased from 3.4% in 1993 to 10.3%
in 1997 [20]. The distribution of ESBL genotypes
in Taiwan is very similar to that of mainland
China, with early reports of SHV-5 ⁄ 12 and
b-lactamases, followed by a growing dominance
of isolates with CTX-M-3 ⁄ 14 b-lactamases [21]. As
in most other Asian countries, in Taiwan TEM
ESBLs are rare, with only TEM-10 having been
reported [22].
The ﬁrst report of ESBL-producing bacteria
from Taiwan was prompted by a marked increase
in ceftazidime resistance among K. pneumoniae (to
30% of all isolates) in 1997 [23]. Isoelectric
focusing of b-lactamases was used; pIs above 7.0
were found in all cases, and it was presumed that
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ESBLs were SHV types. DNA sequencing of PCR
products from SHV-speciﬁc primers revealed
22 isolates with SHV-5 and two with SHV-2;
seven others had pIs of either 7.9 or 7.75, and it is
likely that these were unrecognised CTX-M types
[23]. Subsequent surveys have demonstrated
variations in the distribution of genotypes
among species of Enterobacteriaceae, with CTX-
M-3 ⁄ SHV-12 in K. pneumoniae and CTX-M-3 in
E. coli, Serratia marcescens and non-typhoidal Sal-
monella [19]. CTX-M-14 is less frequently seen
than in mainland China but is common in Proteus
mirabilis [24], and SHV-12 is the most common
ESBL in E. cloacae [19].
The evolution of different genotypes of SHV
ESBLs has been postulated to be due to the
accumulation of mutations in either SHV-1 or -11
(both non-ESBLs) [25]. The relative abundance of
SHV ESBLs in Taiwan results from their early
emergence and mass spread of the common
successful genotypes (e.g., SHV-5 ⁄ 12). One study
supports the notion that SHV-2 ⁄ -5 ⁄ -12, and rarer
types, SHV-26 and the non-ESBL type SHV-25,
have evolved by stepwise mutation, the latter two
possibly from SHV-1 and SHV-11, respectively
[26].
SOUTH KOREA
One of the earliest documented reports of the
occurrence of ESBL phenotypes comes from
Korea, with 7.5% of E. coli and 22.8% of K. pneu-
moniae isolates at Yonsei Medical Center being
described as ESBL-positive in 1994 [27]. Interest-
ing subsequent studies on genotypes in the late
1990s showed a pattern very different from that
of other Asian countries. Unusually, TEM-52 was
one of the most frequently encountered ESBLs in
E. coli and K. pneumoniae from three centres in
1996, produced by 22 ⁄ 53 isolates, often in com-
bination with other genotypes, against 26 ⁄ 53
with SHV-12 and 14 ⁄ 53 with SHV-2a [27]. When
36 blood culture isolates of E. coli and K. pneu-
moniae from 1994–1996 were characterised, the
majority produced TEM-52 but two produced
TEM-15 and two produced TEM-88. No particu-
lar hydrolytic kinetic advantages were found for
TEM-52 and TEM-88 over the parental type
TEM-15 [28].
A retrospective study of isolates from Seoul,
Korea in 1995–1996 revealed one isolate of E. coli
and two of K. pneumoniae producing CTX-M-14
[29], an enzyme ﬁrst described in Guangzhou,
China in 1997–1998 [14]. The prevalence of bac-
teria with CTX-M ESBLs in Korea has since grown
but not to the extent seen in mainland China.
A survey in 2005 reported 23 ⁄ 246 E. coli isolates
and 55 ⁄ 239 K. pneumoniae isolates with an ESBL
phenotype, and overall, only 26 had CTX-M
enzymes [12]. Strains with CTX-M-14 were not
common (13 reported), and those with CTX-M-3
and CTX-M-15 were even less common. It should
be noted, in this context, that CTX-M-15 differs
from CTX-M-3 by only one amino acid substitu-
tion, Gly240Asp, which could be a de-novo
evolutionary event. However, as CTX-M-15 has
probably been present in India for some consid-
erable time, and is present in both E. coli and
Klebsiella spp. at a high frequency, spread from
India is more likely [30]. Although blaCTX-M-15 has
subsequently spread to many parts of the world,
it remains very rare in Asia, supporting this
hypothesis [31]. CTX-M-9 was also reported in
isolates from three Korean hospitals in 2003 [32],
and recently, CTX-M-12, which has three amino
acid changes from CTX-M-3, was reported. It has
been reported previously (and rarely) only from
Kenya, Colombia and China [33]. GES-3, a rare
ESBL previously reported only from Greece and
Japan, has also been found in Korea [12].
JAPAN
As in Korea, the pattern of ESBL genotypes in
Japan is quite different from that seen in sur-
rounding countries, although universally success-
ful types, e.g., CTX-M-14, have recently become
more common. Although some surveys suggest
that the overall rate of ESBL phenotypes is
comparatively low (6.5% in E. coli, 11.0% in
K. pneumoniae [5]) ESBLs have been present for a
long time. Studies by Kawakami et al. [34] from a
hospital in Tokyo reported rates of 0.4% and 0.6%
in E. coli and K. pneumoniae, respectively, in 1990,
rising to 1.7% and 7.2% in 1995. A survey of
seven laboratories in the Kinki region, over 2-
month periods in 1998 and 2000, revealed 10% of
E. coli isolates and 4.0% of K. pneumoniae isolates
to have an ESBL phenotype. Molecular genotyp-
ing revealed 13 isolates of S. marcescens producing
CTX-M-3 and CTX-M-3, and SHV-12 was found
in K. pneumoniae and E. coli [35]. In a survey of 426
urinary isolates of E. coli from patients in 37
hospitals on Northern Kyushu Island between
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January and September 2003, the overall ESBL
rate was 14%. Sixteen hospitals reported ESBLs,
and among these, ‡40% of isolates produced
ESBLs [36]. The diversity of rates probably reﬂects
differences in cross-infection rates and in local
antibiotic usage. The most recent countrywide
survey, unfortunately, does not include denomi-
nator data [37].
Two very early members of the CTX-M group
were identiﬁed in Japan: TOHO-1 and -2. These
have not spread or evolved de novo outside Japan,
except for one reported single isolate producing
TOHO-1 from Argentina [1]. TOHO-1 (CTX-M-
44) is very closely related to CTX-M-2, and was
reported in relation to an isolate of E. coli col-
lected in 1993 [1,3]. TOHO-2 (CTX-M-45) was
described a short time later and is only distantly
related (by amino acid sequence) to CTX-M-9.
TOHO-1 (CTX-M-44) and TOHO-2 (CTX-M-45)
have recently been given numbers in the CTX-M
series (http://www.Lahey.org-internet-studes-in-
c_webt.asp). The precise frequency of occurrence
of TOHO-1 (TOHO-2) has never been reported in
epidemiological studies, and the veracity of the
sequence has been questioned [38], as it is so
closely related to CTX-M-2, and many studies in
Japan have used group-speciﬁc PCRs or DNA
probes that would not differentiate among these
genotypes. A major survey from Tokyo in 1997–
1998, undertaken to ascertain the presence of
SHV- and TEM-derived ESBLs, revealed
28 ⁄ 16 805 E. coli isolates and 41 ⁄ 9794 K. pneumo-
niae isolates with ESBL phenotypes [10]. TOHO
group enzymes were more common in E. coli, and
SHV-12 enzymes, in particular, were more com-
mon in K. pneumoniae, while only a single exam-
ple of a TEM ESBL, TEM-26, was found. A much
more recent survey of the whole of Japan again
used only group-speciﬁc PCR to identify CTX-M
genotypes, but again conﬁrmed the frequent occur-
rence of the CTX-M-2 group. The CTX-M-9 group
(possibly CTX-M-14) and the CTX-M-1 groupwere
almost as frequent as the CTX-M-2 group [37]. All
isolates of P. mirabilis and some Acinetobacter spp.
produced only CTX-M-2, possibly due to the
limited range of the plasmid host [37]. In this
study, genotyping using PCR for blaCTX-M was
carried out only on 317 isolates, phenotypically
thought to carry blaCTX-M (more resistant to
cefotaxime than ceftazidime). In total, 1456
Gram-negative bacilli that were resistant to oxyi-
mino-cephalosporins, from 132 hospitals, were
submitted for study; those showing other patterns
of resistance or a negative double-disk-diffusion
test were excluded from study, as potentially
leading to bias [37] The spread of CTX-M-2 into
Acinetobacter is a worrying development and may
relate to its carriage by a class 1 integron, facili-
tating transfer among different replicons. A report
of cross-infection in a neurosurgical unit among
three patients, due to Acinetobacter baumannii
isolates carrying a plasmid encoding CTX-M-2,
all of which had a restriction endonuclease
pattern identical to a plasmid in a contempora-
neous P. mirabilis isolate, demonstrates the impor-
tance of plasmid transfer in the spread of blaCTX-M
[39].
INDIA AND PAKISTAN
Both India and Pakistan have reported high rates
of ESBLs since the 1990s [6,8]. ESBL-producing
Enterobacteriaceae are also well-established in the
community, as evidenced by a study of patients
with infections and no prior hospitalisation in the
preceding 3 months. Three hundred isolates were
collected, 72 (24%) being ESBL producers, 50
being from patients in the community; signiﬁ-
cantly, 74% and 76% had a history of prior use, at
some time, of a cephalosporin and quinolone,
respectively [40]. There have been relatively few
genotyping studies, but SHV-12 in K. pneumoniae
has been reported from Southern India to be
linked to the qnrB plasmid-mediated quinolone
resistance determinant, the ﬁrst report being from
S. marcescens [41,42] There is a report of SHV-5
produced by Salmonella senftenberg causing an
outbreak on a burns ward in Delhi [43]. The only
genotype of a TEM ESBL is TEM-104, reported in
ten isolates of K. pneumoniae from New Delhi in
2001–2002 [7]. CTX-M-15 b-lactamase is now
widely distributed across the world, but was ﬁrst
described in a small number of isolates from
Delhi in 2000 [44]. A very recent survey from
three widely dispersed centres in India showed
that 95 ⁄ 130 cefpodoxime-resistant E. coli and
K. pneumoniae isolates obtained between 2003
and 2005 carried a blaCTX-M gene, which, when
genotyped using reverse-line hybridisation [45]
and DNA sequencing, was shown to be blaCTX-M-15
in all cases [30]. The study by Ensor et al.
prompted a letter reporting on isolates of Klebsi-
ella spp. and E. coli collected in the late 1990s from
six widely dispersed centres; 47 isolates were
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examined using PCR and DNA sequencing, and
37 were found to carry blaCTX-M-15, which was the
only CTX-M genotype found [46]. CTX-M-15 was
also identiﬁed from two of the K. pneumoniae
isolates collected during 2002–2003 in Coimbatore
in South India [41]. India, therefore, not only
appears to have very high rates of ESBL produc-
tion across the country, but is entirely dominated
by blaCTX-M-15, with no other blaCTX-M genotypes
having yet been detected.
Surveys of ESBLs from Pakistan have, to date,
only reported on the occurrence of ESBL pheno-
types. An early survey by Zaman et al., of 200
nosocomial isolates of Enterobacteriaceae, re-
ported a rate of 35% [8]. A comprehensive study
of both hospital (Aga Khan Hospital, Karachi,
Pakistan) and community isolates of E. coli, Kle-
bsiella spp. and Enterobacter spp. revealed ESBL
phenotype rates of 41%, 36% and 50%, respec-
tively; the overall rate for the 2840 isolates
collected between April and October 2002 was
40% [8]. The rate of isolation of ESBLs was
highest among inpatients (52%) and lowest in
patients from community health centres (30%). At
the time of writing, there have been no genotyp-
ing studies. A recent paper suggested the identi-
ﬁcation of CTX-M-producing bacteria, but this
was based on the fact that the MIC of cefotaxime
is higher than that of ceftazidime in four isolates
of E. coli, and no molecular data were reported
[47].
OTHER ASIAN COUNTRIES
High rates of the ESBL phenotype (26% of
Enterobacteriaceae) were reported as early as
1994–1996 in Khon Kaen, northern Thailand [48].
A genotyping study of those isolates found that
26 ⁄ 43 produced SHV-12, 13 ⁄ 43 SHV-5, 2 ⁄ 43 SHV-
2a and 1 ⁄ 43 VEB-1 [49]. VEB-1 is always reported
to be encoded on a cassette as part of a class I
integron; in addition to being reported from
several species of Enterobacteriaceae, blaVEB-1
has been found in multiple isolates of Pseudomo-
nas aeruginosa in Thailand, illustrating its consid-
erable genetic mobility [50]. The VEB series of
b-lactamases was originally described in Vietnam
(hence, Vietnamese extended-spectrum b-lactam-
ase), and involved 14 of 55 ESBL-producing
Enterobacteriaceae. While 14 carried blaCTX-M-like
genes, DNA sequencing of Klebsiella spp. isolates
revealed six of these genes to be blaCTX-M14 and
two its close relative, blaCTX-M17, with blaSHV-2
being found in 21 isolates [51]. There are few
detailed reports of ESBLs from other Asian
countries, but a recent study from Malaysia
reported blaSHV-5 to be the dominant ESBL there
[52].
CONCLUSION
Asia, like many other regions of the world, has
experienced a signiﬁcant increase in the numbers
of ESBL-producing bacteria in the new millen-
nium. The current rates in some countries are
very high and there are clues that the CTX-M
enzymes, which are responsible for much of the
increase, have been present since the late 1980s.
A recent study of isolates of Enterobacteriaceae
causing community-acquired infection in multi-
ple Chinese centres revealed surprisingly high
rates of ESBL production (E. coli 16%, Klebsiella
spp. 17%) [53]. This, combined with disquieting
evidence that food animals studied in Hong Kong
(but largely raised on the mainland) carried the
same distribution of CTX-M genotypes as is seen
in human infections [54], suggests that these
resistance genes are set to become as common as
blaTEM-1. Faecal carriage rates of ESBL producers
are likely to be high, and the spread of Entero-
bacteriaceae through poor-quality drinking water
and poor sewage disposal probably accounts for
this situation. With the populations of India and
China standing at 1.1 billion and 1.4 billion,
respectively, these two countries surely represent
the largest reservoirs of CTX-M ESBL genes in the
world. Increasing travel and trade will contribute
to the worldwide spread of locally evolved CTX-
M genotypes.
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